menu
    • menu
    [{"orgOrder":0,"company":"Notable Labs","sponsor":"Oncoheroes Biosciences Inc.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Volasertib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Notable Labs \/ Oncoheroes Biosciences Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Oncoheroes Biosciences Inc."},{"orgOrder":0,"company":"Notable Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Volasertib","moa":"PLK-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Notable Labs \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Notable Labs \/ Not Applicable"},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Fosciclopirox","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"7","companyTruncated":"Notable Labs \/ CicloMed LLC"},{"orgOrder":0,"company":"Notable Labs","sponsor":"VBL Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Volasertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ VBL Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ VBL Therapeutics"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Builders VC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Volasertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Notable Labs \/ Builders VC","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ Builders VC"},{"orgOrder":0,"company":"Notable Labs","sponsor":"VBL Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Merger","leadProduct":"Volasertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Notable Labs \/ Notable Labs","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ Notable Labs"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Notable stockholders Builders VC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Private Placement","leadProduct":"Volasertib","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Notable Labs \/ Notable stockholders Builders VC","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ Notable stockholders Builders VC"},{"orgOrder":0,"company":"Notable Labs","sponsor":"CicloMed LLC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Fosciclopirox","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ CicloMed LLC","highestDevelopmentStatusID":"8","companyTruncated":"Notable Labs \/ CicloMed LLC"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Volasertib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Notable Labs","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Volasertib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Notable Labs","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Notable Labs \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Notable Labs \/ Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Pipeline Developments & Deals by Notable Labs

    Menu

    Notable Labs

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

                            Details : NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myeloid leukemia.

                            Brand Name : NBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 24, 2024

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Notable Advances in Volasertib Phase 2 Program Using Precision Medicine for Enrollment

                            Details : NBL-001 (volasertib) is a PLK-1 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory acute myelogenous leukemia.

                            Brand Name : NBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 22, 2024

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome

                            Details : CPX-POM (fosciclopirox) is a patented, parentally administered prodrug of a commercially available topical antifungal agent, ciclopirox. It is under phase 1/2 clinical development for the treatment of bladder cancer and Acute Myeloid Leukemia (AML).

                            Brand Name : CPX-POM

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 18, 2023

                            Lead Product(s) : Fosciclopirox

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : VBL Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Notable Labs Closes Merger Transaction with VBL Therapeutics

                            Details : The Merger will focus on developing new precision medicines through Notable’s proprietary Predictive Precision Medicines Platform. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and apoptosis ...

                            Brand Name : NBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : VBL Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Notable stockholders Builders VC

                            Deal Size : $10.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Notable Labs Closes Merger Transaction with VBL Therapeutics

                            Details : The Merger will create a company developing new precision medicines through Notable’s proprietary Predictive Precision Medicines Platform (PPMP). NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest...

                            Brand Name : NBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Notable stockholders Builders VC

                            Deal Size : $10.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : VBL Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

                            Details : The Merger will create a clinical-stage therapeutic platform company developing new precision medicines through Notable’s proprietary PPMP. NBL-001 (volasertib) is derived from PPMP and is a highly potent PLK1 inhibitor inducing cell cycle arrest and a...

                            Brand Name : NBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : VBL Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Builders VC

                            Deal Size : $10.3 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

                            Details : Notable’s lead asset derived from PPMP is NBL-001 (volasertib), a highly potent PLK1 inhibitor proven to induce cell cycle arrest and apoptosis in various cancer cells.

                            Brand Name : NBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Builders VC

                            Deal Size : $10.3 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosciclopirox,Cytarabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under ...

                            Details : Under the terms of co-development agreement, CicloMed holds the responsibility for executing clinical trial operations while Notable is focused on optimizing Notable’s predictive precision medicine platform with the goal of assessing patient responsive...

                            Brand Name : CPX-POM

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 01, 2021

                            Lead Product(s) : Fosciclopirox,Cytarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CicloMed LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Oncoheroes Biosciences Inc.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Oncoheroes Biosciences Inc. Out-licences Volasertib to Notable Labs for the Global Adult Development of Its An...

                            Details : Under the terms of this agreement, Oncoheroes will retain the license for the development and commercialization of volasertib for pediatric cancers and continue its commitment towards childhood cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 11, 2021

                            Lead Product(s) : Volasertib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Oncoheroes Biosciences Inc.

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            Notable Labs

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Volasertib,Cytarabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volas...

                            Details : Volasertib is a Polo-like kinase 1 (PLK-1) inhibitor with demonstrated activity in AML and other tumor types with significant unmet medical need. Company plan to fast-track volasertib’s development with phase 2/3 clinical trials in AML and other cancer...

                            Brand Name : NBL-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 11, 2021

                            Lead Product(s) : Volasertib,Cytarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth